Journal
JOURNAL OF PATHOLOGY
Volume 223, Issue 1, Pages 15-27Publisher
WILEY
DOI: 10.1002/path.2766
Keywords
cancer; pharmacogenetics; pharmacogenomics; chemotherapy; clinical application; TYMS; DPYD; UGT1A1; CYP2D6; EGFR; KRAS; FCGR3A; BRCA1/2
Funding
- Korean Ministry of Education, Science and Technology [FPR08A2-130]
- Ministry of Health, Welfare and Family Affairs, Republic of Korea [A070001]
Ask authors/readers for more resources
Significant efforts to develop pharmacogenomic predictors have been made to guide more effective and safer chemotherapy. Although a considerable amount of data has been generated from numerous experimental or clinical studies, there is a large gap between pharmacogenomic knowledge and clinical application. This review will focus on eight pharmacogenetic tests including TYMS, DPYD, UGT1A1, CYP2D6, EGFR, KRAS, FCGR3A, and BRCA1/2 to predict toxicity or response to commonly used chemotherapeutic agents. We will discuss the current level of evidence, if the current pharmacogenetic tests are appropriate for clinical application, and how to integrate the pharmacogenomic information into routine clinical practice. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available